Introduction to Hepatitis B
Hepatitis B, often dubbed “serum hepatitis,” is a serious liver infection caused by the hepatitis B virus (HBV). It presents a pressing global health challenge, especially in tropical and developing regions. Hepatitis B may manifest as an acute or chronic disease, ranging from mild, asymptomatic illness to life-threatening liver failure or cancer.
Globally, hepatitis B has been responsible for a significant number of Disability-Adjusted Life Years (DALYs), particularly in countries like India and Sudan. Despite the availability of vaccines and effective treatments, millions remain unaware of their status or are inadequately treated due to systemic gaps in healthcare.
Understanding the Epidemiological Triad
Agent Factors
HBV is a double-shelled DNA virus, known as the Dane particle, capable of surviving outside the body for at least seven days. It comes in three morphological forms and is highly infectious. Humans are the only known reservoir, and the virus can spread via infected blood, saliva, semen, or vaginal fluids.
Host Factors
Infants and young children are especially vulnerable, with infections acquired early in life having a higher chance of becoming chronic. High-risk groups include healthcare workers, sex workers, intravenous drug users, recipients of blood transfusions, and people with compromised immune systems.
Environmental Factors
Environmental risks play a significant role, especially in under-resourced healthcare settings. Unsafe injection practices, unregulated blood transfusions, improper waste disposal, and cultural practices like non-sterile tattooing contribute to transmission.
Global Distribution of Hepatitis B
The burden of hepatitis B varies widely. Tropical and developing nations bear the brunt of the disease, with high prevalence noted in India for DALYs and in Sudan for DALYs per 100,000 population. Conversely, high-income nations with better vaccination and healthcare infrastructure report significantly lower rates.
The WHO categorizes HBV endemicity into four groups based on HBsAg prevalence, guiding vaccination and prevention policies accordingly.
Modes of Transmission
HBV is transmitted primarily through:
- Parenteral transmission: Via blood and blood products.
- Perinatal transmission: From mother to child during childbirth.
- Sexual transmission: Especially among high-risk populations.
- Horizontal transmission: Among children through open wounds or shared items like razors or toothbrushes.
The incubation period ranges from 30 to 180 days, influenced by the viral dose and individual immune response.
Risk Factors for Hepatitis B
Certain populations are disproportionately affected:
- Infants: Especially those born to HBV-positive mothers.
- Healthcare professionals: Due to needle-stick injuries and patient exposure.
- Sexually active individuals: Particularly those with multiple partners.
- People with compromised immunity: Including organ transplant recipients.
Early exposure increases the likelihood of developing chronic infection, emphasizing the importance of neonatal vaccination.
Natural History and Clinical Course
The clinical spectrum of HBV includes:
- Acute Hepatitis B: May resolve spontaneously with lifelong immunity.
- Fulminant Hepatitis: A rare, severe form requiring urgent liver transplant.
- Chronic Hepatitis B: Can progress to liver cirrhosis, portal hypertension, hepatocellular carcinoma, and eventual liver failure.
Diagnostic Markers of HBV Infection
HBV diagnosis is based on specific antigens and antibodies:
| Antigen/Antibody | Significance |
|---|---|
| HBsAg | Active infection |
| HBeAg | High infectivity |
| Anti-HBs | Recovery or immunity |
| Anti-HBc (IgM) | Acute infection |
| Anti-HBc (IgG) | Chronic or past infection |
Epidemiological Paradox in Rural vs Urban Settings
A curious observation in India showed higher hepatitis B prevalence in rural areas despite better vaccination coverage than urban counterparts. This paradox may stem from differences in healthcare access, hygiene practices, or underreporting in urban regions. Behavioral and socio-cultural dynamics also influence health-seeking behavior and disease spread.
Treatment Options for Hepatitis B
There’s no specific antiviral treatment for acute hepatitis B. Management is supportive—hydration, nutrition, and rest. However, chronic hepatitis B requires long-term therapy:
- First-line agents: Tenofovir and entecavir.
- Administration: One pill daily, lifelong in many cases.
- Interferon-based therapy: Less favored due to high cost and side effects.
These treatments reduce liver damage, slow disease progression, and lower cancer risk.
Preventive Strategies
Prevention is the cornerstone of HBV control:
- Vaccination: Routine childhood immunization (e.g., 6, 10, 14 weeks) drastically cuts transmission. Adults require doses at 0, 1, and 6 months.
- HBIG (Hepatitis B Immunoglobulin): Offers immediate protection post-exposure; ideally administered within 6–48 hours.
- Other measures: Blood screening, sterilization practices, and education.
WHO’s 5C Approach to Hepatitis
To ensure ethical and effective screening and treatment, WHO promotes:
- Consent
- Confidentiality
- Correct test results
- Counseling
- Connection to care
This model ensures patient rights and fosters better linkage to services.
Public Health Measures for HBV Control
- Strengthening infection control in hospitals.
- Enforcing blood donor screening.
- Promoting community education on hygiene and vaccination.
These strategies have shown success in lowering hepatitis B rates in various countries.
Challenges in Low and Middle-Income Countries
These include:
- Limited access to vaccines and diagnostics.
- Cultural stigma and misinformation.
- Underfunded public health systems.
International support and local policy changes are crucial to overcoming these barriers.
The Role of Health Education
Education campaigns targeting schools, workplaces, and communities play a critical role. Informing the public about transmission routes, preventive measures, and vaccination can dramatically reduce incidence rates.
Surveillance and Research Priorities
Robust data collection helps track progress and identify gaps. Research into newer, shorter-duration therapies and needle-free vaccines is ongoing and holds promise for broader implementation.
Frequently Asked Questions (FAQs)
Q1. How is hepatitis B transmitted?
Via blood, body fluids, perinatal, and sexual contact.
Q2. Can hepatitis B be cured?
Acute hepatitis B may resolve on its own; chronic cases can be managed but not fully cured.
Q3. Is the vaccine safe?
Yes, it’s highly effective and recommended for all age groups.
Q4. How long does hepatitis B virus survive outside the body?
Up to 7 days on surfaces.
Q5. Who should get tested for hepatitis B?
All high-risk groups, pregnant women, and those with abnormal liver function tests.
Q6. Can hepatitis B cause cancer?
Yes, it can lead to hepatocellular carcinoma if chronic.
Conclusion
Hepatitis B is a formidable public health challenge, but with vaccination, early detection, and consistent treatment, it is controllable. Understanding its epidemiology empowers both healthcare providers and communities to act decisively. Together, through education, prevention, and policy, we can reduce the global burden of hepatitis B.
MCQs
Direct MCQs (Knowledge-Based)
1. What is the causative agent of Hepatitis B?
A. RNA virus
B. Dane particle
C. Protozoa
D. Retrovirus
✅ Answer: B. Dane particle
2. What is the size of the Hepatitis B virus?
A. 60 nm
B. 42 nm
C. 100 nm
D. 24 nm
✅ Answer: B. 42 nm
3. What is the incubation period range for Hepatitis B?
A. 10–20 days
B. 15–60 days
C. 30–180 days
D. 5–10 days
✅ Answer: C. 30–180 days
4. Which of the following is NOT a mode of transmission of HBV?
A. Airborne droplets
B. Parenteral exposure
C. Perinatal transmission
D. Sexual contact
✅ Answer: A. Airborne droplets
5. Which antigen is also called the Australia antigen?
A. HBcAg
B. HBsAg
C. HBeAg
D. Anti-HBc
✅ Answer: B. HBsAg
6. What is the first-line treatment recommended by WHO for chronic Hepatitis B?
A. Interferon alpha
B. Tenofovir or Entecavir
C. Lamivudine
D. Acyclovir
✅ Answer: B. Tenofovir or Entecavir
7. What is the primary prevention strategy for Hepatitis B?
A. Antibiotics
B. Hepatitis B vaccine
C. Liver transplant
D. Passive immunity only
✅ Answer: B. Hepatitis B vaccine
8. What is the risk of chronic infection if HBV is acquired in infancy?
A. Low
B. Moderate
C. High
D. Zero
✅ Answer: C. High
9. Which of the following is a host factor increasing risk of infection?
A. Proper vaccination
B. Young age at infection
C. Use of PPE
D. Handwashing
✅ Answer: B. Young age at infection
10. According to WHO’s 5C principles, what does the second ‘C’ stand for?
A. Commitment
B. Counseling
C. Confidentiality
D. Community outreach
✅ Answer: C. Confidentiality
Applied MCQs (Scenario-Based)
11. A healthcare worker sustains a needle-stick injury while treating a known HBV-positive patient. What should be the immediate next step?
A. Wait and monitor symptoms
B. Administer antibiotics
C. Administer Hepatitis B immunoglobulin (HBIG) and start vaccine series
D. Do nothing if asymptomatic
✅ Answer: C. Administer Hepatitis B immunoglobulin (HBIG) and start vaccine series
12. In a region with >90% vaccination coverage, what is the expected HBV prevalence?
A. Remains unchanged
B. Increases gradually
C. Drops from ~10% to <1%
D. Increases due to vaccine resistance
✅ Answer: C. Drops from ~10% to <1%
13. A 3-year-old child in a developing country has been diagnosed with chronic HBV. What is the most probable reason?
A. Nosocomial transmission
B. Perinatal transmission
C. Airborne transmission
D. Adult-to-child spread via food
✅ Answer: B. Perinatal transmission
14. A patient shows HBsAg and Anti-HBc (IgG) positivity. What does this indicate?
A. Acute infection
B. Recovery
C. Chronic infection
D. Vaccination response
✅ Answer: C. Chronic infection
15. A community survey shows that rural areas have higher HBV prevalence than urban areas despite higher vaccination coverage. What could explain this?
A. Poor hygiene practices
B. Better healthcare access
C. Reverse causality
D. Overreporting
✅ Answer: A. Poor hygiene practices
16. A patient recovering from HBV infection shows only Anti-HBs in lab tests. What does this imply?
A. Chronic infection
B. Acute infection
C. Immunity after infection or vaccination
D. False positive
✅ Answer: C. Immunity after infection or vaccination
17. Why is Tenofovir preferred in chronic HBV treatment in developing countries?
A. Costly but effective
B. Less side effects and low resistance risk
C. Requires injection
D. Fast viral clearance
✅ Answer: B. Less side effects and low resistance risk
18. A lab technician tests positive for Anti-HBc (IgM). What does this indicate?
A. Past infection
B. Current acute infection
C. Chronic carrier state
D. Vaccination response
✅ Answer: B. Current acute infection
19. Which of the following is most likely to contribute to HBV spread in traditional communities?
A. Exclusive breastfeeding
B. Ritual circumcision using unsterile tools
C. Modern diagnostic tests
D. Clean water supply
✅ Answer: B. Ritual circumcision using unsterile tools
20. A newborn is born to an HBV-positive mother. What preventive strategy offers the best protection?
A. Wait for symptoms
B. Immediate vaccination only
C. Passive immunization only
D. Combined vaccine + HBIG within 24 hours
✅ Answer: D. Combined vaccine + HBIG within 24 hours
DoctorDP 